Kairos Pharma, LTD.
About Kairos Pharma, LTD.
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$5.4M
- Total assets
- $6.5M
- Market cap
- $9.4M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $9.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 16, 2024
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Kairos Pharma, LTD..
